Sputum cytokine repeatability in COPD

<bold>Background:</bold> Immunoassays are commonly used to assess airway inflammation in sputum samples from COPD patients. We have previously validated a Luminex assay able to quantify 20 analytes in sputum supernatant according to current regulatory standards [1]. The repeatability of these biomarkers over time in COPD patients is not known. <bold>Methods:</bold> Biomarkers were measured in paired sputum supernatant samples from COPD patients collected 6 and 12 months apart (n=48 and 18 respectively) using the validated assay. <bold>Results:</bold> 14 panel analytes were detectable. Repeated sputum biomarker measurements showed a significant positive correlation between baseline and 6 months for 13 analytes with intraclass correlation coefficient (ICC) indicating excellent repeatability (>0.75) for 7 analytes (Table 1). Similar results were observed at 12 months. <bold>Conclusion:</bold> This study demonstrates good to excellent repeatability over time in a panel of sputum supernatant biomarkers quantified using a validated Luminex assay. [1] Mulvanny, A et al, Biomedicines 2022; 10, 1949. <bold>Table 1</bold> <table-wrap><object-id>erj;64/suppl_68/PA2994/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col></colgroup><tbody><tr><td>Analyte</td><td>6 Month Repeatability (<italic>n</italic>=48)</td></tr><tr><td>Correlations (Rho)</td><td>ICC</td></tr><tr><td>IL-1β</td><td>0.62***</td><td>0.78</td></tr><tr><td>IL-1RA</td><td>0.26</td><td>0.42</td></tr><tr><td>IL-2</td><td>0.67***</td><td>0.80</td></tr><tr><td>IL-4</td><td>0.54***</td><td>0.63</td></tr><tr><td>IL-6</td><td>0.50**</td><td>0.72</td></tr><tr><td>IL-8</td><td>0.57***</td><td>0.71</td></tr><tr><td>Eotaxin</td><td>0.50**</td><td>0.67</td></tr><tr><td>G-CSF</td><td>0.64***</td><td>0.85</td></tr><tr><td>IFN-γ</td><td>0.37*</td><td>0.41</td></tr><tr><td>IP-10</td><td>0.72***</td><td>0.83</td></tr><tr><td>MCP-1</td><td>0.44*</td><td>0.55</td></tr><tr><td>MIP-1α</td><td>0.64***</td><td>0.79</td></tr><tr><td>MIP-1β</td><td>0.72***</td><td>0.86</td></tr><tr><td>TNF-α</td><td>0.57***</td><td>0.79</td></tr></tbody></table><table-wrap-foot> *p<0.01, **p<0.001, ***p<0.0001 </table-wrap-foot></table-wrap>

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa2994
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sputum cytokine repeatability in COPD

Alex Mulvanny, Augusta S. Beech, Dave Singh, T. Parra
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Sputum cytokine repeatability in COPD

Alex Mulvanny, Augusta S. Beech, Dave Singh, T. Parra
article en

Abstract

<bold>Background:</bold> Immunoassays are commonly used to assess airway inflammation in sputum samples from COPD patients. We have previously validated a Luminex assay able to quantify 20 analytes in sputum supernatant according to current regulatory standards [1]. The repeatability of these biomarkers over time in COPD patients is not known. <bold>Methods:</bold> Biomarkers were measured in paired sputum supernatant samples from COPD patients collected 6 and 12 months apart (n=48 and 18 respectively) using the validated assay. <bold>Results:</bold> 14 panel analytes were detectable. Repeated sputum biomarker measurements showed a significant positive correlation between baseline and 6 months for 13 analytes with intraclass correlation coefficient (ICC) indicating excellent repeatability (>0.75) for 7 analytes (Table 1). Similar results were observed at 12 months. <bold>Conclusion:</bold> This study demonstrates good to excellent repeatability over time in a panel of sputum supernatant biomarkers quantified using a validated Luminex assay. [1] Mulvanny, A et al, Biomedicines 2022; 10, 1949. <bold>Table 1</bold> <table-wrap><object-id>erj;64/suppl_68/PA2994/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col></colgroup><tbody><tr><td>Analyte</td><td>6 Month Repeatability (<italic>n</italic>=48)</td></tr><tr><td>Correlations (Rho)</td><td>ICC</td></tr><tr><td>IL-1β</td><td>0.62***</td><td>0.78</td></tr><tr><td>IL-1RA</td><td>0.26</td><td>0.42</td></tr><tr><td>IL-2</td><td>0.67***</td><td>0.80</td></tr><tr><td>IL-4</td><td>0.54***</td><td>0.63</td></tr><tr><td>IL-6</td><td>0.50**</td><td>0.72</td></tr><tr><td>IL-8</td><td>0.57***</td><td>0.71</td></tr><tr><td>Eotaxin</td><td>0.50**</td><td>0.67</td></tr><tr><td>G-CSF</td><td>0.64***</td><td>0.85</td></tr><tr><td>IFN-γ</td><td>0.37*</td><td>0.41</td></tr><tr><td>IP-10</td><td>0.72***</td><td>0.83</td></tr><tr><td>MCP-1</td><td>0.44*</td><td>0.55</td></tr><tr><td>MIP-1α</td><td>0.64***</td><td>0.79</td></tr><tr><td>MIP-1β</td><td>0.72***</td><td>0.86</td></tr><tr><td>TNF-α</td><td>0.57***</td><td>0.79</td></tr></tbody></table><table-wrap-foot> *p<0.01, **p<0.001, ***p<0.0001 </table-wrap-foot></table-wrap>

University of Manchester (GB), Medicines Evaluation Unit (GB)
Zero hunger
Openalex Percentile: Top 63%
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.